Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2010 Jan 15;20(2):516-20. doi: 10.1016/j.bmcl.2009.11.097. Epub 2009 Nov 23.

Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.

Author information

1
Discovery Chemistry, Pfizer Global Research and Development, Sandwich, United Kingdom. Alan.D.Brown@pfizer.com

Abstract

A series of aryloxyazetidines, aryloxypyrrolidines and aryloxypiperidines were designed based on structural overlap with previously reported arylpyrazine Oxytocin antagonists. Similarly high levels of Oxytocin antagonism were achievable in these new series. Several aryloxyazetidines also showed high levels of selectivity, with one compound, 25, displaying promising in vivo pharmacokinetics and significantly improved aqueous solubility over related compounds containing a biaryl substituent.

PMID:
19963374
DOI:
10.1016/j.bmcl.2009.11.097
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center